Patents by Inventor Frank John Schoenen

Frank John Schoenen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cephalosporin derivatives and methods of use
    Patent number: 10059722
    Abstract: This invention provides cephalosporin derivatives for killing or inhibiting the spread of microorganisms such as non-replicating Mycobacterium tuberculosis and in the treatment of infectious disease.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: August 28, 2018
    Assignee: UNIVERSITY OF KANSAS
    Inventors: Jeffrey Aube, Carl Nathan, Robert Smith, Ben S. Gold, Paul Hanson, Chunjing Liu, Lester Allen Mitscher, Maneesh Pingle, Frank John Schoenen
  • INHIBITORS OF THE MITF MOLECULAR PATHWAY
    Publication number: 20170334842
    Abstract: Provided herein are compounds of the formula (IV): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer.
    Type: Application
    Filed: July 7, 2017
    Publication date: November 23, 2017
    Inventors: Patrick FALOON, Warren S. WEINER, Robert A. SMITH, Frank John SCHOENEN, David E. FISHER, Rizwan HAQ
  • Inhibitors of the MITF molecular pathway
    Patent number: 9745261
    Abstract: Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: August 29, 2017
    Assignees: THE GENERAL HOSPITAL CORPORATION, THE BROAD INSTITUTE, INC., UNIVERSITY OF KANSAS
    Inventors: Patrick Faloon, Warren S. Weiner, Robert A. Smith, Frank John Schoenen, David E. Fisher, Rizwan Haq
  • Kappa opioid receptor effectors and uses thereof
    Patent number: 9540375
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: January 10, 2017
    Assignees: University of Kansas, The Scripps Research Institute
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin J. Frankowski
  • HCV helicase inhibitors and methods of use thereof
    Patent number: 9464064
    Abstract: The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: October 11, 2016
    Assignees: University of Kansas, UWM Research Foundation, Inc.
    Inventors: Jeffrey Aube, Brian Scott Jonathan Blagg, Kevin John Frankowski, David Norman Frick, Kelin Li, Frank John Schoenen
  • Salicylic acid derivatives useful as glucocerebrosidase activators
    Patent number: 9464035
    Abstract: Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 11, 2016
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF KANSAS
    Inventors: Juan Jose Marugan, Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Elma Aflaki, Steven Andrew Rogers, Frank John Schoenen
  • KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF
    Publication number: 20160257685
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Application
    Filed: May 17, 2016
    Publication date: September 8, 2016
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin J. Frankowski
  • Kappa opioid receptor effectors and uses thereof
    Patent number: 9345703
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 24, 2016
    Assignees: University of Kansas, The Scripps Research Institute
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin John Frankowski
  • INHIBITORS OF THE MITF MOLECULAR PATHWAY
    Publication number: 20160130222
    Abstract: Provided herein are compounds of the formula (IV) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful as MITF inhibitors, MITF pathway inhibitors and for the treatment of cancer.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 12, 2016
    Inventors: Patrick FALOON, Warren S. WEINER, Robert A. SMITH, Frank John SCHOENEN, David E. FISHER, Rizwan HAQ
  • CEPHALOSPORIN DERIVATIVES AND METHODS OF USE
    Publication number: 20150322087
    Abstract: This invention provides cephalosporin derivatives for killing or inhibiting the spread of microorganisms such as non-replicating Mycobacterium tuberculosis and in the treatment of infectious disease.
    Type: Application
    Filed: November 4, 2013
    Publication date: November 12, 2015
    Inventors: Jeffrey Aube, Carl Nathan, Robert Smith, Ben S. Gold, Paul Hanson, Chunjing Liu, Lester Allen Mitscher, Maneesh Pingle, Frank John Schoenen
  • SALICYLIC ACID DERIVATIVES USEFUL AS GLUCOCEREBROSIDASE ACTIVATORS
    Publication number: 20150065469
    Abstract: Compounds of Formula (I) and the pharmaceutically acceptable salts thereof are disclosed. The variables. R1-R13, m, n, o, and p are disclosed herein. The compounds are useful for treating Gaucher disease and inhibiting the onset of Gaucher disease symptoms in a patient having a GBA gene mutation and for treating Parkinson's disease. Pharmaceutical compositions containing compounds of Formula (I) and methods of treatment comprising administering compounds of Formula (I) are also disclosed.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 5, 2015
    Inventors: Juan Jose Marugan, Wei Zheng, Samarjit Patnaik, Noel Southall, Ellen Sidransky, Ehud Goldin, Wendy Westbroek, Elma Aflaki, Steven Andrew Rogers, Frank John Schoenen
  • KAPPA OPIOID RECEPTOR EFFECTORS AND USES THEREOF
    Publication number: 20140371227
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Application
    Filed: September 14, 2012
    Publication date: December 18, 2014
    Applicants: The Scripps Research Institute, University of Kansas
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin John Frankowski
  • HCV Helicase Inhibitors and Methods of Use Thereof
    Publication number: 20140227225
    Abstract: The present invention discloses thioflavine S and primuline derivatives which inhibit hepatitis C virus helicase and protease activity. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are useful as antiviral agents. The present invention further relates to pharmaceutical compositions containing the aforementioned compounds and methods of treating an HCV infection.
    Type: Application
    Filed: September 7, 2012
    Publication date: August 14, 2014
    Applicants: UWM RESEARCH FOUNDATION, INC., UNIVERSITY OF KANSAS
    Inventors: Jeffrey Aube, Brian Scott Jonathan Blagg, Kevin John Frankowski, David Norman Frick, Kelin Li, Frank John Schoenen
  • Compositions and Methods for Establishing and Maintaining Stem Cells in an Undiffferentiated State
    Publication number: 20120270313
    Abstract: The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.
    Type: Application
    Filed: May 24, 2012
    Publication date: October 25, 2012
    Applicant: University of Kansas
    Inventors: Soumen Paul, Debasree Dutta, Soma Ray, Jeffrey Aube, Frank John Schoenen
  • Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
    Patent number: 8193235
    Abstract: The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: June 5, 2012
    Assignee: University of Kansas
    Inventors: Soumen Paul, Debasree Dutta, Soma Ray, Jeffrey Aube, Frank John Schoenen
  • Compositions and methods for establishing and maintaining stem cells in an undifferentiated state
    Publication number: 20100317100
    Abstract: The present invention embraces compositions and methods for establishing and maintaining stem cells and inhibiting stem cell differentiation using a selective Protein Kinase C (PKC) inhibitor.
    Type: Application
    Filed: June 11, 2010
    Publication date: December 16, 2010
    Inventors: Soumen Paul, Debasree Dutta, Soma Ray, Jeffrey Aube, Frank John Schoenen